These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9719498)

  • 41. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
    Giaccone G; van Ark-Otte J; Scagliotti G; Capranico G; van der Valk P; Rubio G; Dalesio O; Lopez R; Zunino F; Walboomers J
    Biochim Biophys Acta; 1995 Dec; 1264(3):337-46. PubMed ID: 8547322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A-62176, a potent topoisomerase inhibitor, inhibits the expression of human epidermal growth factor receptor 2.
    Kim HL; Jeon KH; Jun KY; Choi Y; Kim DK; Na Y; Kwon Y
    Cancer Lett; 2012 Dec; 325(1):72-9. PubMed ID: 22732416
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of DNA topoisomerases in chronic proliferative kidney disease.
    Ivanova LV; Rudolph P; Kellner U; Jürgensen A; Tareeva IE; Alm P; Proppe D
    Kidney Int; 2000 Oct; 58(4):1603-12. PubMed ID: 11012894
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
    Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
    Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.
    Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Jul; 92(7):799-805. PubMed ID: 11473732
    [TBL] [Abstract][Full Text] [Related]  

  • 46. All-trans retinoic acid suppresses topoisomerase IIα through the proteasomal pathway.
    Li X; Li Y; Shen X; Fu S; Han S; Feng Q
    Anticancer Drugs; 2015 Aug; 26(7):737-46. PubMed ID: 25946380
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts.
    Thielmann HW; Popanda O; Gersbach H; Gilberg F
    Carcinogenesis; 1993 Nov; 14(11):2341-51. PubMed ID: 8242865
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression.
    Hopfner R; Mousli M; Jeltsch JM; Voulgaris A; Lutz Y; Marin C; Bellocq JP; Oudet P; Bronner C
    Cancer Res; 2000 Jan; 60(1):121-8. PubMed ID: 10646863
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Active DNA topoisomerase IIalpha is a component of the salt-stable centrosome core.
    Barthelmes HU; Grue P; Feineis S; Straub T; Boege F
    J Biol Chem; 2000 Dec; 275(49):38823-30. PubMed ID: 11006289
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Induction of alkylator (melphalan) resistance in HL60 cells is accompanied by increased levels of topoisomerase II expression and function.
    Pu QQ; Bezwoda WR
    Mol Pharmacol; 1999 Jul; 56(1):147-53. PubMed ID: 10385695
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.
    Turley H; Comley M; Houlbrook S; Nozaki N; Kikuchi A; Hickson ID; Gatter K; Harris AL
    Br J Cancer; 1997; 75(9):1340-6. PubMed ID: 9155056
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Delphinidin modulates the DNA-damaging properties of topoisomerase II poisons.
    Esselen M; Fritz J; Hutter M; Marko D
    Chem Res Toxicol; 2009 Mar; 22(3):554-64. PubMed ID: 19182879
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y; Takano H; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Repair of gamma-ray-induced DNA base damage in xeroderma pigmentosum cells.
    Fornace AJ; Dobson PP; Kinsella TJ
    Radiat Res; 1986 Apr; 106(1):73-7. PubMed ID: 3961106
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Threonine 1342 in human topoisomerase IIalpha is phosphorylated throughout the cell cycle.
    Ishida R; Iwai M; Marsh KL; Austin CA; Yano T; Shibata M; Nozaki N; Hara A
    J Biol Chem; 1996 Nov; 271(47):30077-82. PubMed ID: 8939955
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells.
    Magan N; Isaacs RJ; Stowell KM
    Anticancer Drugs; 2012 Jul; 23(6):627-37. PubMed ID: 22293659
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
    Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
    Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does polysomy of chromosome 17 have a role in ERBB2 and topoisomerase IIalpha expression? Gene, mRNA and protein expression: a comprehensive analysis.
    Corzo C; Bellosillo B; Corominas JM; Salido M; Coll MD; Serrano S; Albanell J; Solé F; Tusquets I
    Tumour Biol; 2007; 28(4):221-8. PubMed ID: 17717428
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proneness to UV-induced apoptosis in human fibroblasts defective in transcription coupled repair is associated with the lack of Mdm2 transactivation.
    Conforti G; Nardo T; D'Incalci M; Stefanini M
    Oncogene; 2000 May; 19(22):2714-20. PubMed ID: 10851071
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.
    Yamazaki K; Isobe H; Hanada T; Betsuyaku T; Hasegawa A; Hizawa N; Ogura S; Kawakami Y
    Cancer Chemother Pharmacol; 1997; 39(3):192-8. PubMed ID: 8996519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.